It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Uncleaved prefusion-optimized (UFO) design can stabilize diverse HIV-1 envelope glycoproteins (Envs). Single-component, self-assembling protein nanoparticles (1c-SApNP) can display 8 or 20 native-like Env trimers as vaccine candidates. We characterize the biophysical, structural, and antigenic properties of 1c-SApNPs that present the BG505 UFO trimer with wildtype and modified glycans. For 1c-SApNPs, glycan trimming improves recognition of the CD4 binding site without affecting broadly neutralizing antibodies (bNAbs) to major glycan epitopes. In mice, rabbits, and nonhuman primates, glycan trimming increases the frequency of vaccine responders (FVR) and steers antibody responses away from immunodominant glycan holes and glycan patches. The mechanism of vaccine-induced immunity is examined in mice. Compared with the UFO trimer, the multilayered E2p and I3-01v9 1c-SApNPs show 420 times longer retention in lymph node follicles, 20-32 times greater presentation on follicular dendritic cell dendrites, and up-to-4 times stronger germinal center reactions. These findings can inform future HIV-1 vaccine development.
Here the authors present an HIV-1 vaccine strategy that combines Env stabilization, nanoparticle display, and glycan trimming, which improves neutralizing antibody responses, frequency of vaccine responders, and germinal center reactions in animal models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231)
2 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231); The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231)
3 University of Southampton, School of Biological Sciences, Highfield Campus, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297)
4 Texas Biomedical Research Institute, Southwest National Primate Research Center, San Antonio, USA (GRID:grid.250889.e) (ISNI:0000 0001 2215 0219)
5 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231); The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231); The Scripps Research Institute, The Skaggs Institute for Chemical Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231)
6 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231); The Scripps Research Institute, Department of Immunology and Microbiology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231)